medigraphic.com
Colegio de Medicina Interna de México.

2019, Number 2

<< Back Next >>

Med Int Mex 2019; 35 (2)

Leukocytoclastic vasculitis (hypersensitivity vasculitis)

Hernández-López A, Panigua-Tapia MU, Cortés-Rojo C, Rodríguez-Orozco AR

Language: Spanish
References: 108
Page: 251-267
PDF size: 284.90 Kb.


ABSTRACT

Leukocytoclastic vasculitis is an autoimmune disorder that affects small vessels, and causes inflammation, destruction and necrosis of the same. It is often underdiagnosed. The etiology is multifactorial, the pathophysiology is complex and immunomodulators are the most important medications in their treatment. This article aims to review the current state of knowledge in leukocytoclastic vasculitis with emphasis on diagnosis and treatment. Articles published in the period from 1990 to 2017 were reviewed. The browsers were Google Crome and Firefox and the search engine was Scholar google. The database consulted was: MEDLINE, RIMA Astra-Zeneca and the clinical practice guidelines of the Mexican health system (CENETEC); 108 relevant publications to the subject were reviewed, prioritizing those belonging to journals indexed in MEDLINE and Science Citation Index-JCR. Studies are required to integrate clinical and treatment subgroups and investigate the mechanisms of tissue damage in each subgroup. Immunomodulation plays a central role in the treatment.


REFERENCES

  1. Langford CA, Faucy AS. The vasculitis syndromes. In: Kasper DL, Fauci AS, Hauser SL et al, editors. Harrison Principles of internal medicine. 19th ed. USA: McGraw-Hill; 2015:2179-2193.

  2. Katz P. Vasculitis. In: Austen KF, Frank MM, Atkinson JP et al. Samter’s Immunologic Diseases. 6th ed. Philadelphia USA: Lippincott Williams & Wilkins; 2001:560-571.

  3. Karatropak C, Arabaci E, Yildiz K et al. Gastroenterology Cases of Cutaneous Leukocytoclastic Vasculitis. Hindawi Publishing Corporation 2013;2013: 1-4.

  4. Langford CA. Vasculitis. J Allergy Clin Immunol 2010;125(2):S216-S225.

  5. Condemi JJ, Dykewickz MS, Bielory L et al. Alergia e Inmunología MKSAP, segunda ed. Mexico: Inter Sistemas; 2003:209-217.

  6. Liste S, Chamizo MG, Paz LE et al. Vasculitis leucocitoclástica. Revista Cubana de Medicina General Integral 2013;30(4):415-420.

  7. Ting TV. Diagnosis and management of cutaneous vasculitis in children. Pediatr Clin N Am 2014;321-346.

  8. Einhorn J, Levis JT. Dermatologic Diagnosis: Leukocytoclastic Vasculitis. Perm J 2015;19(3):77-78.

  9. Arora A, Wetter DA, Gonzalez TM et al. Incidence of leukocytoclastic vasculitis, 1996 to 2010: A populationbased study in Olmsted County, Minnesota. Mayo Clin Proc 2014:1-10.

  10. Bouiller K, Audia S, Devilliers H et al. Etiologies and prognostic factors of leukocytoclastic vasculitis with skin involvement. A retrospective study in 112 patients. Wolters Kluwer Health 2016;95(28):1-8.

  11. Pulido A, Aviles JA, Suarez R. Vasculitis cutáneas. Actas Dermosifiliogr 2012;103(3):179-191.

  12. Wollina U, Schönlebe J. Segmental leukocytoclastic vasculitis in herpes zoster. Int J Dermatol 2012;51:1351-1352.

  13. Lee HJ, Shin DH, Choi JS et al. Leukocytoclastic vasculitis associated with influenza A virus infection. J Korean Med Sci 2012; 27:1601-1603.

  14. Santa Maria Garcia MS, Morales C, Noguerado B, et al. Cutaneous leukocytoclastic vasculitis due to amoxicillin hypersensitivity. Ann Allergy Asthma Immunol 2016;117:446-447.

  15. Moawad S, Bursztejn AC, Schmutz JL et al. Vasculite Leucocytoclasique annulaire: une forme particulière de vasculite des petits vaisseaux? Ann Dermatol Vénéréol 2016;143:364-368.

  16. Singh D, Durkan AM. Pediatric vasculitis. Indian J Pediatr 2016;83(2):156-162.

  17. Chastain MA, Russo GG, Boh EE et al. Propylthiouracil hypersensitivity: Report of two patients with vasculitis and review of the literature. J Am Acad Dermatol 1999;41(5):757-764.

  18. Garcia MC, Hierro S, Achell L et al. Vasculitis leucocitoclástica posvacunación contra influenza: Comunicación de un caso y revisión de la bibliografía. Dermatologia Rev Mex 2010;54 (2):80-83.

  19. Hessert MJ, Devlin J. Ink Sick: Tattoo ink hypersensitivity vasculitis. Am J Emerg Med 2011:29;1237.e3-1237.e4.

  20. Purai N, Jain T, Bhanot R et al. Levamisole-induce leukocytoclastic vasculitis and neutropenia in a patient with cocaine use: An extensive case with necrosis of skin, soft tissue, and cartilage. Addict Sci Clin Pract 2012;7(19):1-10.

  21. Espitia O, Dréno B, Cassagnau E et al. Exercise-induced vasculitis: A review with illustrated cases. Am J Clin Dermatol 2016;1-8.

  22. Ugarte ML, Tejeda O. Vasculitis leucocitoclástica a propósito de 3 casos. Revista Informacion e Investigacion Médica Universidad del Valle 2012;7(18):72-86.

  23. Cordova VH, Vega CA, Masse S et al. Vasculitis leucocitoclástica y procesos linfoproliferativos: micosis fungoide. Med Int Mex 2012;28(3):293-297.

  24. Kumar V, Abbas AK, Aster JC. Diseases of the immune system. In: Kumar V, Abbas AK, Aster JC, editors. Robbins basic pathology. 9th ed. Philadelphia USA: Elsevier; 2013:109-120.

  25. Wollenhaupt J, Reich K. Hautmanifestationen der verschiedenen Vaskulitiden. Zeitschrift für Rheumatologie 2013;72:436-444.

  26. Teng GG, Chatham WW. Vasculitis related to viral and other microbial agents. Best Pract Res Clin Rheumatol 2015;29:226-243.

  27. Monach Paul, Merkel P, American College of Rheumatology, 2015, [consultado 17 Diciembre 2017] Disponible en: http://www.rheumatology.org/I-Am-A/Patient-Caregiver/ Diseases-Conditions/Vasculitis

  28. Pollack S. Hypersensitivity angiitis. In: Schoenfeld Y, Cervera R, Gershwin ME, editors. Diagnostic criteria in autoimmune diseases. New Jersey, USA: Humana Press; 2008:141-145.

  29. Meza CM, Dehesa E, Ruelas AG et al. Vasculitis leucocitoclástica: Un reto diagnóstico para el médico internista. Med Int Mex 2015;31:113-118.

  30. Jennette JC, Falk RJ, Bacon PA et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. J Am Coll Rheumatol 2013;65(1):1-11.

  31. Khanna G, Sargar K, Baszis KW. Pediatric vasculitis: Recognizing multisystemic manifestations at body imaging. RadioGraphics 2015;35:849-865

  32. Carlson JA, Cavaliere LF, Grant JM. Cutaneous vasculitis: diagnosis and management. Clin Dermatol 2006;24:414-429.

  33. Weisman MH, Weinblatt ME, Louie JS. Tratamientos en reumatología: Enfoque vasculitis. En: Weisman MH, Weimblat ME, Louie JS. 2ª ed. Madrid, España: Marbán; 2003:182-184.

  34. Gross WL, Trabandt A, Reinhold-Keller E. Diagnosis and evaluation of vasculitis. Rheumatology (Oxford) 2000;39:245-52.

  35. Stacy PA, Feels E, Langford CA et al. Cutaneus vasculitis: Relationship to systemic disease and therapy. Curr Prob Dermatol Med Clin 1993;2(10):45-80.

  36. Carlson JA, Chen KR. Cutaneous vasculitis update: small vessel neutrophilic vasculitis syndromes. Am J Dermatopathol 2006;28:486-506.

  37. Sais G, Vidaller A, Jucgla A, Servitje O et al. Prognostic factors in leukocytoclastic vasculitis. Arch Dermatol 1998;134:309-15.

  38. Chen O, Zhu XB, Ren P, et al. Henoch Schonlein purpura in children: clinical analysis of 120 cases. Afr Health Sci 2013;13(1):94-9.

  39. Calvino MC, Llorca J, Garcia-Porrua C, et al. Henoch- Schonlein purpura in children from northwestern Spain: a 20-year epidemiologic and clinical study. Medicine 2001;80(5):279-90.

  40. Peru H, Soylemezoglu O, Bakkaloglu SA, et al. Henoch Schonlein purpura in childhood: clinical analysis of 254 cases over a 3-year period. Clin Rheumatol 2008; 27(9):1087-92.

  41. Jorizzo JL. Classification of vasculitis. J Invest Dermatol 1993;100:106S-110S.

  42. Carlson JA, Ng BT, Chen KR. Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. Am J Dermatopathol 2005;27(6):504-28.

  43. Radice A, Sinico RA. Antineutrophil cytoplasmic antibodies (ANCA). Autiinmunity 2005;38:93-103.

  44. Chen KR, Carlson JA. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol 2008;9(2):71-92.

  45. Demirkesen C. Approach to cutaneous vasculitides with special emphasis on small vessel vasculitis: histopathology and direct immunofluorescence. Wolters Kluwer Health 2017;29:39-44.

  46. Flores LP. Vasculitis. En: Martinez P. Introducción a la Reumatología [Introduction to Rheumatology]. 3ra ed. México DF: Fondo Editorial CMR; 2003:319-331.

  47. Sergent JS. Vasculitis. In: Panush RS. Principles of rheumatic diseases. 1st ed. New York, USA: John Wiley & Sons; 1990:331-362.

  48. Loricera J, González C, Blanco R et al. Histopathologic differences between cutaneous vasculitis associated with severe bacterial infection and cutaneous vasculitis secondary to other causes: a study of 52 patients. Clin Exp Rheumatol 2016;34:S93-S97.

  49. Mitchell RN. Blood Vessels. In: Kumar V, Abbas AK, Aster JC, editors. Robbins basic pathology. 9th ed. Philadelphia USA: Elsevier; 2013:327-363.

  50. Bahrami S, Malone JC, Webb KG et al. Tissue eosinophilia as an indicator of drug-induced cutaneous small-vessel vasculitis. Arch Dermatol 2006;142:155-61.

  51. Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 2005;90(9):916-20.

  52. Soliman M, Laxer R, Manson D et al. Imaging of systemic vasculitis in childhood. Pediatr Radiol 2015;45:1110- 1125.

  53. Ozen S, Ruperto N, Dillon M, et al EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitis. Ann Rheum Dis 2006;65:936-94.

  54. Saulsbury FT Henoch-Schonlein purpura. Curr Opin Rheumatol 2001;13:35-40.

  55. De Vega T, Blanco S, Lopez C, et al. Clarythromycin induced lekocitoclastic vasculitis (letter). Eur J Clin Microbio Infect Dis 1933;12(7):5.

  56. Wagh S, Karmarker D, Rajput C. Ciprofloxacine induced hypersensitivity vasculitis syndrome (letter). Indian J Pediatr 1993;608(4):610-611.

  57. Herranz S, Durán M, Trallero R, et al. Scurvy: an unusual cause of purpura, ecchymosis and arthralgias. Rev Clin Esp 2007; 207:481.

  58. Kluger N, Francès C. Cutaneous vasculitis and their differential diagnoses. Clin Exp Rheumatol 2009;27:124-38.

  59. Carlson JA, Chen KR. Cutaneous pseudovasculitis. Am J Dermatopathol 2007;29:44-55.

  60. Francés C, Kluger N, Doutre M-S. Vasculitis cutáneas y cutaneosistémicas. Dermatología 2011;45:1-20.

  61. Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol 2009;10:365.1.

  62. Warrinton KJ, Matteson EL. A primer on vasculitis. Minn Med 2013;96:36-39.

  63. De Menthon M, Mahr A. Treating polyarteritis nodosa: current state of the art. Clin Exp Rheumatol 2011;29:S110- 116.

  64. Dillon MJ, Eleftheriou D, Brogan PA. Medium-size-vessel vasculitis. Pediatr Nephrol 2010;25:1641-1652.

  65. Blanca M, Romano A, Torres MJ et al. Update on the evaluation of hypersensitivity reactions to betalactams. Allergy 2009;64:183-193.

  66. Lunardi C, Bambara LM, Biasi D, et al. Elimination diet in the treatment of select patients with hypersensibility vasculitis. Clin Exp Rheumatol 1992;10:131-135.

  67. Blanco R, Martinez-Taboada VM, Rodriguez Valverde V, et al. Cutaneous vasculitis in children and adults. Associated diseases and etiologic factors in 303 patients. Medicine 1998;77:403-418.

  68. Barnadas MA, Perez E, Gich I, et al. Diagnostic, prognostic and pathogenicvalue of the direct immunofluorescence test in cutaneous leukocytoclastic vasculitis. Int J Dermatol 2004;43(1):19-26.

  69. Kliegman RM, Stanton BF, St.Geme III JW, et al. Nelson Tratado de pediatría. 19ª ed. Barcelona España. Elsevier. 2011;909

  70. Szer IS. Gastrointestinal and renal involvement in vasculitis: management strategies in Henoch-Schonlein purpura. Cleve Clin J Med 1999;66(5):312-7.

  71. Millins JL, Randle HW, Scolley GO et al. The therapeutic response of urticarial vasculitis to indomethacin. J Am Acad Dermatol 1980;31:349-355.

  72. Wahba-Yahav AV: Chronic cutaneous leukocytoclastic vasculitis associated with polycytemia vera: Effective control with pentoxifylline. J Am Acad Dermatol 1992;26:1006- 1007.

  73. Katz SI, Gallin, JI, Hertz KC et al. Erythema elevatum diutinum: Skin and systemic manifestations, immunologic study, and successful treatment with dapsone. Medicine 1977;56:443-455.

  74. Nürnberg W, Grabbe J, Gzarnetzki BM: Synergistic effects of pentoxifylline and dapsone in leukocytoclastic vasculitis. Lancet 1994;343:491.

  75. Callen JP. Colchicine is effective in controlling chronic cutaneous leukocytoclastic vasculitis. Arch Dermatol 1991;127:515-522.

  76. Sais G, Vidaller A, Jucglá A et al. Colchicine in the treatment of cutaneous leukocytoclastic vasculitis: Results of a prospective, randomized controlled trial. Arch Dermatol 1995;131:1399-1402.

  77. Bano-cho M, Nawata H, Takayanag R, Takaoka K, Fukunaga R, et al. Guideline for management of vasculitis syndrome, Circulation J 2011;75:474-503.

  78. Ronkainen J, Koskimies O, Ala-Houhala M, et al. Early prednisone therapy in Henoch-Schonlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr 2006;149:241-7.

  79. Mukhtyar C, Guillevin L, Cid MC et al; European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009;68:310-317.

  80. Gayraud M, Guillevin L, le Toumelin P et al. Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001;44:666- 675.

  81. Fauci AS, Katz P, Haynes BF et al. Cyclosphosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 1979;301:235-238.

  82. Lapraik C, Watts R, Bacon P et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology 2007;46:1615-1616.

  83. Langford CA, Talar-Williams C, Barron KS et al. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003;114:463-469.

  84. Fauci AS, Braunwald EB, Kasper DL et al. Harrison’s principles of internal medicine, 18th ed. McGraw-Hill: New York; 2011;2786-2798.

  85. Hakim A, Clunie G, Haq I. Manual Oxford de Reumatología: Vasculitis primarias. 2ª ed. Madrid, España: Grupo Aula médica SL; 2008;442-475.

  86. Walters GD, Willis NS, Craig JC. Interventions for renal vasculitis in adults. A systematic review. BMC Nephrol 2010;24:11-12.

  87. Dandan RH, Brunton LL. Goodman y Gilman Manual de farmacología y terapéutica: Inmunosupresores, Tolerógenos e Inmunoestimulantes. 2ª ed. Estados Unidos de América: McGraw-Hill Interamericana editores; 2015:650-667.

  88. Callen JP, Spencer LV, Burrus JB, et al. Azatioprine: An effective, corticosteroid sparing therapy for patients with recalcitrant cutaneous lupus erytematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 1991;127:515-522.

  89. Heurkens AHM, Westedt ML, Breedvel FC. Prednisone plus azathiopruine treatment in patients with rheumatoid arthritis complicated by vasculitis. Arch Intern Med 1991;151:22249-2254.

  90. Jorizzo JL, White WL, Wise CM, et al. Low-dose weekly methotrexate for unusual vascular reactions: Cutaneous polyarteritis nodosa and Becet’s disease. J Am Acad Dermatol 1991;24:973-978.

  91. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-2469.

  92. Hu W, Liu C, Xie H, et al. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 2008;23:1307-1312.

  93. Stassen PM, Tervaert JW, Stegeman CA. Induction of remission in active anti-neutrophil cytoplasmic antibodyassociated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2007;66:798-802.

  94. Romero Vázquez, et al. Revista Alergia México 2016;63(3):278-282

  95. Fauci AS, Haynes BF, Katz P. The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med 1978;89:660-76.

  96. Langford CA, Sneller MC. Biologic therapies in the vasculitides. Curr Opin Rheumatol 2003;15:3-10.

  97. Miloslavsky EM, Specks U, Merkel PA, et al. Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 2014;66:3151-3159.

  98. Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 2012;51:634-643.

  99. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221-232.

  100. Jones RB, Tervaert JW, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-220.

  101. Holle JU, Dubrau C, Herlyn K et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener’s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 2012;71:327-333.

  102. Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti-TNFalpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology 2002;41:1126-1132.

  103. Booth A, Harper L, Hammad T, et al. Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004;15:717-721.

  104. McIlwain L, Carter JD, Bin-Sagheer S, et al. Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab. J Clin Gastroenterol 2003;36(5):411-413.

  105. Díaz-Orta MA, Rojas-Serrano J. Biologic therapies in the systemic vasculitides. Reumatol Clin 2011;7:33-36.

  106. Rodríguez Orozco AR. Mecanismos de acción de la inmunoglobulina humana en las enfermedades dermatológicas pediátricas. Rev. Cubana Pediatr 2007;79(4):510-534.

  107. Gómez Ortiz ME, Pinto Peñaranda LF, Muñoz-Grajales C et al. Plasmaféresis y recambio terapéutico de plasma en enfermedades autoinmunes: indicaciones, complicaciones y desenlaces. Descripción de una serie de casos. Rev Colomb Reumatol 2014;21(3):139-145.

  108. Szpirt WM, Heaf JG, Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener’s granulomatosis--a clinical randomized controlled trial. Nephrol Dial Transplant 2011;26:206-213.




2020     |     www.medigraphic.com